Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2024-06-10 Regulatory Filings
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Trading and Funding Update
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 7052R' and contains the standard closing information for an RNS announcement, including contact details and a disclaimer about RNS being the news service of the London Stock Exchange. The content itself is a 'TRADING AND FUNDING UPDATE' discussing working capital requirements, expected funding timelines (Q3 2024), revenue expectations, and strategic decisions regarding product development (AT278). This type of operational and financial update, disseminated via the Regulatory News Service (RNS), is best classified as a general Regulatory Filing (RNS) because it does not fit the specific criteria for an Earnings Release (ER, which is usually just the highlights), an Interim Report (IR, which is a comprehensive financial statement), or a Capital Update (CAP, which is usually about a specific financing event). Since it is a broad, timely announcement via the official regulatory channel, RNS is the most appropriate general category.
2024-06-10 English
Posting of 2023 Annual Report and Notice of AGM
AGM Information Classification · 98% confidence The document is a short announcement (3420 chars) released via RNS (RNS Number : 6699Q) on May 31, 2024. The title explicitly states: 'POSTING OF ARECOR 2023 ANNUAL REPORT AND NOTICE OF AGM'. The body confirms that the company 'has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 December 2023 and Notice of the Annual General Meeting ("AGM")' and provides a link to view/download them. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report (like the Annual Report or AGM Notice) rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA). Although it mentions AGM and Annual Report, the primary function of this specific filing is to announce their availability.
2024-05-31 English
Grant of Options and PDMR Dealing
Director's Dealing Classification · 98% confidence The document is an official announcement filed via RNS (RNS Number : 5522P) from Arecor Therapeutics PLC. The primary content details the 'Grant of Options and PDMR Dealing' for several executives (Persons Discharging Managerial Responsibilities). This type of filing, which reports personal share transactions (specifically option grants) by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific subject matter is insider trading/dealing, making DIRS the most precise classification over the general RNS fallback.
2024-05-23 English
Arecor to host company and KOL webinar today
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date (21 May 2024) and company information, typical of a regulatory news service announcement. The content announces a corporate event (a webinar) to discuss clinical trial results and provides contact details and boilerplate information about RNS/LSE. Since it is an announcement about an upcoming event/information release rather than the full report itself (like 10-K or IR), and it is clearly a general regulatory announcement distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not a specific type like ER, DIV, or DIRS, making RNS the best fit as a general regulatory announcement.
2024-05-21 English
Positive headline results for AT278 clinical trial
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number and is dated May 20, 2024. It announces positive Phase I clinical trial results for a drug candidate (AT278) and includes bullet points summarizing the findings, quotes from the CEO and Principal Investigator, and details about an upcoming webinar to discuss the results. The text explicitly mentions that detailed data will be submitted for publication and presentation at a future conference. Crucially, the document ends with the standard footer indicating it is provided by RNS, the news service of the London Stock Exchange, and contains inside information for UK MAR purposes. This structure is characteristic of a press release or regulatory news service announcement detailing significant corporate or clinical progress, rather than a full financial report (10-K, IR) or a presentation (IP). Since it is a general regulatory announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory filing category.
2024-05-20 English
Final results for 2023
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER). It is titled 'FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023' and contains key financial highlights (revenue, R&D expenses, loss after tax), operational highlights, and management commentary. While it mentions that the full Annual Report will be posted to shareholders in due course, this document itself serves as the initial announcement of the financial results, which fits the definition of an Earnings Release. FY 2023
2024-05-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.